Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio? 4/17/2024

Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space 4/17/2024

Top Q1 Series A Investments Highlight VC Rebound in Biopharma 4/17/2024

Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive 4/17/2024

Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement 4/17/2024

GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data 4/17/2024

Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData 4/17/2024

Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages 4/17/2024

C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries 4/17/2024

Biopharma Layoff Tracker 2024: Fujifilm, Genentech, Sanofi and More Cut Staff 4/17/2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2) The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.

J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales 4/16/2024

Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies 4/16/2024

Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 4/16/2024

Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review 4/16/2024

Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug 4/16/2024

Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome 4/16/2024

Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit 4/16/2024

Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumor. However, ASOs aren’t used for treating cancer yet. They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge. Cancer cells have gatekeeper molecules that stop unwanted substances from entering.

FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Saf... 4/15/2024